Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q
Source: 0001731122-25-000258
Chunk: 111

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q
Item: Part I, Item 8
Chunk 111
---
075) 
     276,241  
     6% 
     (57,884,869) 
     (13,154,189) 
     (44,730,680) 
     340%
  
    393)Other Income (Expenses) 

    Change in fair value of contingent consideration 
     (2,590,000) 
     —  
     (2,590,000) 
     100% 
     6,660,000  
     —  
     6,660,000  
     100%
  
    Loss on extinguishment of debt 
     —  
     —  
     —  
     0% 
     —  
     (120,018) 
     120,018  
     (100)%
  
    Interest expense 
     (98,891) 
     (274,984) 
     176,093  
     (64)% 
     (348,971) 
     (454,255) 
     105,284  
     (23)%
  
    Interest and other income 
     (17,187) 
     15,938  
     (33,125) 
     (208)% 
     109,411  
     24,313  
     85,098  
     350%
  
    Total Other Income (Expense) 
     (2,706,078) 
     (259,046) 
     (2,447,032) 
     945% 
     6,420,440  
     (549,960) 
     6,970,400  
     (1,267)%
  
    NET LOSS 
    $(7,252,394) 
    $(4,529,121) 
    $(2,723,273) 
     60% 
    $(51,464,429) 
    $(13,704,149) 
    $(37,760,280) 
     276%

32

Revenues

We are a pre-revenue, pre-clinical
biotechnology and artificial intelligence driven healthcare technology company. We have never generated revenues and have incurred losses
since inception. We do not anticipate earning any revenue until our therapies or products are approved for marketing and sale.

Expenses